Proton Radiation Therapy for Macular Degeneration

Completed · Not applicable

Conditions studied: Age-Related Macular Degeneration

In brief

This is a pilot study to determine if proton radiation therapy can provide effective and safe treatment for subfoveal neovascularization membrane (SNVM). The study will include adult patients over the age of 50 with macular degeneration, who have subfoveal neovascularization membrane (SNVM) and have had prior treatment with Avastin or Lucentis. Additional purposes of this study are to see if the growth of neovascular membranes can be stopped and overall vision improved with the use of protons and assess the side effects associated with this treatment.

Key facts

Study ID

NCT01833325

Run by

University of Florida

People needed

9

Starts

2013-05-01

Expected to finish

2018-02-01

Last updated by the study team

2018-02-23

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with subfoveal neovascular membranes identified on fluorescein angiography.
• Visual acuity (best corrected vision) 20/200 or worse in affected eye.
• Patient must be 50 years of age or older at time of consent.
• Patients must have had prior treatment for macular degeneration with Avastin (bevacizumab) or Lucentis (ranibizumab).
• Women must be post menopausal or have had a hysterectomy.

You may not qualify if…

• History of diabetes.

Where it is running

• University of Florida Proton Therapy Institute — Jacksonville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.